Barinat 4 Tablet

Introduction

Barinat is a prescription medication that contains the active ingredient Baricitinib. It is available under the brand name Barinat. This medication is primarily used for the treatment of certain inflammatory conditions, such as rheumatoid arthritis.

Uses

Barinat is prescribed to manage the symptoms of rheumatoid arthritis, a chronic autoimmune disease that causes joint pain, stiffness, and inflammation. It helps reduce the signs and symptoms of this condition, including joint swelling, tenderness, and limited mobility.

Dosage and Administration

The dosage of Barinat may vary depending on the individual’s condition and response to treatment. Follow the instructions provided by your healthcare professional. Typically, the recommended starting dose is 2 mg once daily. However, your doctor may adjust the dose based on your specific needs. It is usually taken orally with or without food.

Mechanism of Action

Baricitinib, the active ingredient in Barinat, works by inhibiting certain enzymes in the body that are involved in the inflammatory process. This helps reduce the immune system’s response that leads to joint inflammation and damage in rheumatoid arthritis. By targeting specific pathways, Baricitinib helps to alleviate the symptoms associated with this condition.

Side Effects

Common side effects may include upper respiratory tract infections, headaches, and an increase in cholesterol levels. If these side effects persist or worsen, consult your healthcare professional.

Serious side effects are relatively rare but can occur. These may include an increased risk of infections, liver problems, and changes in blood cell counts. If you experience any of these serious side effects, seek medical attention immediately.

Drug Interactions

Barinat may interact with certain medications, including live vaccines, strong CYP3A4 inhibitors (such as ketoconazole and ritonavir), and immunosuppressive medications. Inform your healthcare professional about all the medications you are currently taking to avoid potential drug interactions.

Precautions

Before starting Barinat, inform your healthcare professional about any existing medical conditions, including allergies, infections, liver problems, or any history of blood disorders. This medication may not be suitable for everyone, and your doctor will consider these factors before prescribing it.

Barinat is not recommended for use during pregnancy or while breastfeeding. It is also contraindicated in individuals with severe liver impairment.

Storage

Barinat should be stored at room temperature, away from moisture and direct sunlight. Keep it out of reach of children and pets. Do not use the medication if it has expired or if the packaging is damaged.

Patient Tips

• Take Barinat exactly as prescribed by your healthcare professional.
• Do not stop or change the dosage without consulting your doctor.
• If you miss a dose, take it as soon as you remember. However, if it is close to the time for your next dose, skip the missed dose and continue with your regular dosing schedule.
• Inform your healthcare professional if you develop any signs of infection, such as fever, cough, or sore throat.
• Regular monitoring of blood tests and liver function may be required while taking this medication.
• If you have any concerns or questions about Barinat, don’t hesitate to reach out to your healthcare professional for further guidance.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Olumiant 1mg Film-Coated Tablets (Health Professionals SmPC) Available at:
• Baricitinib (Drugs.com) [Accessed 3 Jun. 2024] (online) Available at:
• baricitinib tablet (RX) [Accessed 22 Jun. 2024] (online) Available at:
• Baricitinib (MedlinePlus) [Accessed 4 Jun. 2024] (online) Available at:
• King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. [Accessed 9 Jun. 2024] Available at: